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III 
ENGLISH SUMMARY 
Sepsis is a severe response to infection, characterised by systemic inflammation 
leading to tissue damage and organ dysfunction. In septic patients, early, appropriate 
antibiotic treatment is vital, more so in patients with severe sepsis. 
The aim of this PhD project was to further develop an existing causal probabilistic 
network (CPN) model of sepsis through learning: both manually through evidence-
based adjustments to the model and automatically through machine learning from 
patient databases. The model forms part of a larger CPN used by the decision support 
system Treat, which provides advice for optimal antibiotic treatment. 
The results of the project were described in four papers. Paper I described the manual 
learning process where continuous distributions were introduced for infection 
variables. Paper I showed that manual learning is an effective, albeit limited, method 
of constructing a CPN. On a small validation dataset, the manually learned CPN 
presented a non-significant improvement in prediction of patients with bacteraemia 
compared to the previous model. Papers II and III described the automatic learning 
process wherein the model was tuned to function as a standalone predictor of 30-day 
mortality. The tuned model was significantly better than both the previous model and 
other scoring systems described in the literature. Paper IV presented an application 
of the standalone model tuned to predict bacteraemia. It showed that risk-based 
stratification of patients suspected of sepsis could be used to improve the cost-
effectiveness of rapid diagnostics, e.g. polymerase chain reaction, which would 
otherwise be too expensive to use for all patients. 
The resulting models for the prediction of bacteraemia and 30-day mortality can be 
used as standalone systems or reintegrated with the Treat decision support system. 
As a standalone model, the output can be considered as an intelligent biomarker for 
sepsis, tuned from real patient data. Future work involves the development of a more 
complete picture of the inflammatory response, including the time-course, which 
could enable earlier detection of infection or treatment revision in patients for whom 
infections are not microbiologically documented.
 
V 
DANSK RESUME 
Sepsis er kroppens respons til alvorlig infektion, kendetegnet ved systemiske 
inflammation som fører til vævsbeskadigelse og organ dysfunktion. I septiske 
patienter er tidlig, dækkende antibiotika behandling afgørende, desto mere i patienter 
med svær sepsis. 
Formålet af dette PhD projekt var at videreudvikle en existerende kausalt 
probabilistisk netværk (engelsk: Causal Probabilistic Network, eller CPN) model for 
sepsis igennem læring: både manual læring igennem evidens-baserede justeringer af 
modellen og automatisk læring igennem maskin-læring fra patientdatabaser. 
Modellen er en del af et større CPN  inkluderet i beslutningsstøttesystemet Treat, som 
giver råd om optimal antibiotika behandling. 
Projektets resultater blev beskrevet i fire artikler. Artikel I beskrev den manuelle 
læringsproces, hvor kontinuerte fordelinger blev introduceret for infektionsvariabler. 
For et mindre valideringsdatasæt, viste CPN’et baseret på manuel læring ikke 
signifikant forbedring i forudsigelse af patienter med bakteræmi sammenlignet med 
den tidligere model. Artikel II og III beskrev den automatiske læringsproces, hvori 
modellen blev tunet til at fungere som en enestående prædiktor af 30-dages mortalitet. 
Den tunede model var signifikant bedre end både den forrige model og andre 
scoringsystemer beskrevet i literaturen. Artikel IV viste en anvendelse af den 
selvstændige model tunet til at forudsige bakteræmi. Den viste at risiko-baseret 
stratificering af patienter mistænkt for sepsis kunne bruges til at øge cost-
effectiveness af hurtig diagnostiske metoder, f.eks polymerase chain reaction, som 
ville ellers være for dyr til at bruge på alle patienter. 
De resulterende modeller for forudsigelse af bakteræmi og 30-dages mortalitet kan 
bruges som selvstændige systemer eller kan integreres med beslutningsstøttesystemet 
Treat. Anvendt som selvstændigt system, kan outputtet betragtes som en intelligent 
biomarkør for sepsis, tunet fra rigtige patientdata. Fremtidigt arbejde involverer 
udvikling af et mere komplet billede af den inflammatorikse respons, inklusiv 
tidsforløbet, som kunne give mulighed for tidligere detektion af infektion eller 
revidering af behandling af patienter, hvis infektioner ikke er mikrobiologisk 
dokumenteret. 
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CHAPTER 1. INTRODUCTION 
Sepsis is a severe manifestation of a systemic infection and is associated with high 
mortality rates: ranging from 15-60% (Angus et al. 2001, Martin et al. 2003, Vincent 
et al. 2006). Early treatment with appropriate antimicrobials is vital: failure to initiate 
early appropriate antimicrobial therapy increases mortality with an odds ratio of 
approximately 2 (Paul et al. 2010). The decision support system Treat provides 
advice on empirical antimicrobial therapy (before a pathogen is identified) and can 
significantly increase the fraction of patients receiving appropriate antimicrobial 
therapy (Kristensen et al. 1999, Paul et al. 2006b, Leibovici, Paul & Andreassen 
2010, Kofoed et al. 2009), however there are additional clinical decisions during the 
course of an infection that are not addressed by Treat. In chronological order from 
the view of an infectious episode, these are: 1) early detection of the onset of 
infection; 2) risk assessment to determine the diagnostic and treatment strategy; and 
3) revision of therapy a few days after the initiation of therapy. This project focuses 
on the risk assessment of patients suspected of infection. 
Risk assessment of patients suspected of infection serves two purposes: to determine 
the diagnostic strategy and to determine the aggressiveness of empirical therapy. In 
each case, severity of illness is a driving factor. The current standard for sepsis 
diagnosis is blood culture, which typically takes 2-4 days. In comparison, new rapid 
molecular methods such as polymerase chain reaction (PCR) direct from blood are 
much faster, identifying a pathogen in 6-12 hours (Liesenfeld et al. 2014, 
Mwaigwisya, Assiri & O'Grady 2015). Molecular methods are however much more 
expensive, and it is not currently feasible to order these tests for all patients suspected 
of infection. A similar prioritisation exists when considering antimicrobial treatment: 
although broad-spectrum antimicrobials may be able to eradicate most pathogens, 
they have more undesirable side effects, have led to an increase in C. difficile 
infections and widespread increase in resistance to antimicrobials (Vernaz et al. 2009, 
Bartlett 2006, Laxminarayan et al. 2013). In each case, a mathematical risk 
assessment allows for the balancing of costs and benefits. 
Diagnosis and assessment of sepsis severity: SIRS 
Traditionally, the relationship between infection and sepsis is understood to be as 
depicted in Figure 1.1, where SIRS is the Systemic Inflammatory Response 
Syndrome and bacteraemia refers to an infection in the blood-stream. SIRS is a non-
specific state of inflammation, defined at a 1992 consensus conference of the Society 
of Critical Care Medicine and American College of Chest Physicians (Bone et al. 
1992).  
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A patient has SIRS if they meet two or more of the following criteria: 
 Temperature >38°C or <36°C 
 White blood cell (WBC/leukocyte) count <4000 or >12000 cells/cm3 
 Heart rate > 90 bpm (tachycardia) 
 Respiratory rate > 20 breaths per minute 
Sepsis is SIRS caused by an infection and non-infectious SIRS (NSIRS) refers to any 
other aetiology such as trauma/surgery, burns or pancreatitis. Within SIRS and sepsis, 
patients are also graded by severity, for example: severe sepsis is sepsis complicated 
by organ dysfunction, and septic shock is severe sepsis with systolic blood pressure 
less than 90 mmHg, refractory to fluid resuscitation. 
 
Figure 1.1: The relationship between infection, sepsis and SIRS. Other blood-borne 
infections refer to all of those not caused by bacteria. Diagram adapted from (Bone et al. 
1992) 
The idea of SIRS is still part of the most commonly used definition of sepsis, however 
it has been criticised by leading sepsis researchers – it is unspecific and overall not 
very useful (Vincent 1997). In reality, almost all patients with an infection have some 
degree of sepsis: they all have some degree of systemic involvement from the 
immune system. Figure 1.2 proposes an alternate view where patients with an 
infection instead fall into strata based the severity of their sepsis. The state of “no 
sepsis” refers to those with minor infection, for example an infected cut on a finger. 
The proposed states of sepsis severity are somewhat analogous to sepsis, severe 
sepsis and septic shock; the new names allow some departure from the literature 
definitions. 
The continuous severity spectrum described in Figure 1.2 is that used in the Treat 
decision support system. At its core, Treat is a stochastic model of the interaction of 
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Figure 1.2: An alternative view: almost all patients with an infection have some degree of 
sepsis and can be stratified by severity 
bacteria, antimicrobials and the patient’s inflammatory response. This interaction is 
modelled in a Causal Probabilistic Network (CPN). The part of the model which deals 
with the inflammatory response is known as the Sepsis CPN. The Sepsis CPN is the 
main contributor in evaluating the severity of illness. The Sepsis CPN’s performance 
as a diagnostic or prognostic indicator can be evaluated by assessing its ability to 
predict clinical outcomes such as positive blood culture (bacteraemia) and 30-day 
mortality. 
Several other methods for scoring sepsis or (general) illness severity are described in 
the literature. The majority of clinical scores are based on logistic regression models. 
These clinical scores tend to focus on information available at the bedside. Scores 
used for sepsis patients include the modified rapid emergency medicine score 
(mREMS) (Olsson, Terént & Lind 2004, Howell et al. 2007), the mortality in the 
emergency department sepsis (MEDS) score (Shapiro et al. 2003), and the sequential 
organ-failure assessment (SOFA) (Vincent et al. 1996). 
Aim of the PhD study 
The PhD study centres on the development of a family of models for the gradation of 
the severity of sepsis. The starting point for the project is Treat’s Sepsis CPN, with 
the goal of updating the Sepsis CPN and improving its performance in predicting 
bacteraemia and 30-day mortality. The approach taken to solve the problem follows 
GRADATION OF THE SEVERITY OF SEPSIS 
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a Bayesian philosophy: a stepwise updating of a priori understanding based on the 
knowledge available. In this case domain knowledge is acquired from the literature, 
opinions of clinical experts and from patient databases. 
Figure 1.3 presents an overview of the PhD project in three stages. Chapter 2 presents 
the background, including CPN technology and an overview of sepsis and its 
manifestations, Chapters 3 and 4 present the manual and automatic learning stages of 
model development, respectively, and Chapter 5 presents an application of the 
learned SepsisFinder model: selection of high-risk patients for rapid diagnostic 
testing. Chapter 6 then contains a discussion of key points and main findings of the 
thesis, and suggestions for future work. 
 
Figure 1.3: PhD Project Framework 
The initial phase of the PhD project focused on building knowledge and 
understanding of how sepsis develops and the typical markers, signs and symptoms 
seen in patients. Literature concerned with the construction and performance of the 
Treat CPN was also investigated. The Treat CPN serves as an example of a CPN 
model that was constructed largely manually, that is, without applying machine 
learning techniques. A search was also conducted into learning from data in medicine 
and the machine learning methods available, notably expectation maximisation (EM) 
learning. This research was important in building the domain knowledge required to 
successfully construct a CPN and forms the background material presented in 
Chapter 2. 
The next phase of the project focused on model development, shown in the dashed 
box in Figure 1.3. Stepwise improvement of the model via learning was conducted in 
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two stages: first by manual learning (Chapter 3) and then subsequently by automatic 
learning (Chapter 4). 
Chapter 3 summarises the work carried out in the manual learning stage: a set of 
continuous distributions for infection variables that improve Treat’s prediction of 
bacteraemia. The result of the manual learning was the Continuous (C-) Sepsis CPN. 
This method of constructing CPNs was proven to be robust, and was the method used 
in constructing the Treat CPN. This Chapter is based on Paper I. 
Chapter 4 describes the automatic learning process and the results of tuning two 
CPNs: one to predict 30-day mortality and one to predict bacteraemia in patients 
suspected of sepsis. Applying machine learning gives the potential to use the 
knowledge contained in patient databases, something that has not formally been done 
in the Treat model. The result represents a significant improvement over the model 
described in Paper I. This Chapter is based on Papers II and III which described two 
Learned Sepsis CPNs, the L-Sepsis CPN (Paper II) and the LA-Sepsis CPN (Paper 
III) that were tuned to predict 30-day mortality. Chapter 4 also describes the 
SepsisFinder model, which was tuned to predict bacteraemia using a similar learning 
strategy. 
The third and final phase of the project is concerned with the application of the tuned 
SepsisFinder model, and is described in Chapter 5. The SepsisFinder model is used 
for risk-assessment, where the predicted probability of bacteraemia can be used to 
define a group of high-risk patients for whom rapid diagnostic testing may be cost-
effective. Paper IV describes the use of SepsisFinder in assessing the cost-
effectiveness of one rapid diagnostic technique, PCR, in the emergency department. 
This application was also described as part of a patent application (Application 
number: PA 2015 00514) which centred on the idea that one parameter (sepsis 
severity) can be used for many purposes, including but not limited to the prediction 
of bacteraemia and 30-day mortality.  
The main findings and scientific contribution of the thesis are discussed in Chapter 
6. Suggestions for future work are also addressed, including the re-integration of the 
Sepsis CPN within Treat, and the use of Sepsisfinder to describe the time-course of 
infection. A full description of the time-course of infection would provide an 
opportunity to address two of the remaining clinical problems not addressed by Treat: 
early detection of the onset of infection and revision of therapy. 
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CHAPTER 2. BACKGROUND 
This chapter provides the medical and technical background for the PhD project. 
The type of mathematical model used in Sepsisfinder, a Causal Probabilistic Network 
(CPN) is introduced. The basic principles of CPNs including how they are 
constructed and used are explained. The medical problem-area, sepsis, is also 
discussed from the modeller’s perspective, using the Treat CPN as an example. This 
chapter represents the knowledge input to the modelling stage of the PhD project, 
seen as the highlighted portion of Figure 2.1. 
 
Figure 2.1 PhD project framework. This chapter describes the background (highlighted) 
2.1. CPN MODELLING 
CPNs, also referred to as Bayesian networks are a type of stochastic model. A CPN 
can be represented graphically by a set of nodes, linked together by arrows as shown 
in Figure 2.2. The arrows represent causal relationships between variables. 
Numerically these arrows can be thought of as conditional probability tables. The 
task of constructing a CPN consists of specifying the graphical structure and filling 
out the associated conditional probability tables. Once constructed, the CPN updates 
the probability distributions according to the axioms of probability theory based on 
the entered evidence. CPNs are ideal for creating diagnostic models: inferences can 
be made about unobservable variables based on available evidence, and when 
accompanied by decision theory and utility functions they can also provide advice on 
treatment selection. 
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Figure 2.2: Simple CPN model with one cause (Flu) and one effect (Fever). Two tables are 
shown: the top table specifies the a priori likelihood of Flu, and the bottom table is the 
conditional probability table for fever given flu. Adapted from (Andreassen 2000). 
Figure 2.2 contains all the information required for probabilistic reasoning. For 
example, it is possible to calculate the probability for Fever, P(Fever), as the sum of 
the joint probabilities of Fever given Flu as in Equation 2.1: 
P(Fever)=P(Fever|Flu=yes)P(Flu=yes)+P(Fever|Flu=no)P(Flu=no)         (2.1) 
Using Equation 2.1 we can calculate that P(Fever=yes) = 0.90*0.05 + 0.02*0.95 = 
0.064 and P(Fever=no) = 0.10*0.05 + 0.98*0.95 = 0.936. Causal reasoning is simple 
in this case as these probabilities are specified and can be read directly from the 
conditional probability table. The ability to provide diagnostic reasoning, inferring 
the likelihood of a cause based on the observation of an effect is perhaps less 
apparent. Bayes’ Theorem provides the foundation for this type of reasoning; it 
relates the conditional probability of event A given another event B to the conditional 
probability of B given A. In this case A and B are Flu (the cause) and Fever (the 
effect), as in Figure 2.2, and Bayes’ Theorem can be written as: 
P(Flu|Fever)=
P(Flu)P(Fever|Flu) 
P(Fever)
                         (2.2) 
Equation 2.2 is vital to understanding how inference works in CPNs. In this simple 
two variable case, we know the conditional probability P(Fever|Flu) and the a priori 
probability of flu, P(Flu), and then observing Fever=yes, we can solve Bayes’ 
equation to infer the probability of Flu=yes, as in Equation 2.3. The factor 
P(Fever|Flu)/P(Fever) in Equation 2.2 can be seen as the effect of the evidence: the 
factor which the prior probability of Flu (P(Flu)) is multiplied by to give the posterior 
probability. 
P(Flu=yes|Fever=yes)=
P(Flu=yes)P(Fever=yes|Flu=yes)
P(Fever=yes)
=
0.05*0.90
0.064
=0.703               (2.3) 
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The example shown in Figure 2.3 is another simple CPN, this time with two causes: 
flu and throat infection, and two symptoms: fever and sore throat. Fever and sore 
throat can each be caused by flu and/or throat infection, as indicated by the arrows. 
The conditional probability tables are filled out when constructing the CPN, 
specifying the joint probabilities for sore throat and fever respectively, given flu and 
throat infection: P(Fever| Flu, Throat infection) and P(Sore throat | Flu, Throat 
infection) (Figure 2.3, panel A). In this case, observing Fever=no and Sore 
throat=yes allows us to infer that a throat infection is much more likely than the flu 
(Figure 2.3, panel B). 
 
Figure 2.3: Construction and use of a simple CPN. During construction (panel A), the 
structure and probability tables are specified using a top-down approach, following the flow 
of causality. During use (panel B), when the effects are observed, diagnostic reasoning can 
be applied, using the evidence to make inferences about the likely cause. Adapted from 
(Andreassen 2000). 
The example in Figure 2.3 is simple enough that the inferred probabilities could be 
calculated by hand. However, inference quickly becomes complicated as more nodes 
and dependencies are added. For more complex CPNs, software solutions become 
necessary. All CPNs used in this thesis were constructed using the commercial 
software package Hugin (Hugin Expert A/S, Aalborg, Denmark), which was also 
used to perform inference. 
GRADATION OF THE SEVERITY OF SEPSIS 
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2.2. LEARNING IN CPNS 
The construction of a CPN provides a unique opportunity for the fusion of data and 
knowledge. Importantly, this knowledge may come from any one (or more) of a 
number of sources: in the medical domain these could be patient databases, expert 
opinion and reports in the scientific literature. Before beginning construction of a 
model, it is important to understand the problem area: for the infectious process this 
would include the pathogenesis and pathophysiology and what can be observed in a 
patients, for example blood gases, haematology, vital signs etc. The model variables 
and structure are then identified based on the knowledge acquired: this can be done 
manually or automatically, the latter referring to the use of machine learning 
techniques. During the construction of the CPN, the conditional probabilities may 
themselves be considered stochastic variables; a priori distributions may be assigned, 
and the result of learning is the set of a posteriori distributions. 
2.2.1. MANUAL LEARNING 
In the context of this thesis, manual learning refers to the specification of CPN 
structure and conditional probability tables without applying machine learning 
techniques. Manual learning therefore refers to all other forms of knowledge 
acquisition; review and meta-analysis of the scientific literature, uni- or multivariate 
analysis of patient data, or the transformation of expert opinion into explicit 
conditional probabilities. Manual learning can be an effective method for 
constructing CPNs: the Treat CPN, described in section 2.3 was constructed in this 
way. Manual learning was also applied in the construction of the models described 
in this thesis. The specific learning strategy used in described in Chapter 3 which is 
based on Paper I. 
2.2.2. MACHINE LEARNING 
Machine learning from patient data can be used instead of or as a supplement to the 
manual learning process used to construct a CPN. Traditionally, machine learning is 
used to form classification models where cases must be assigned to one of two or 
more groups based on a set of parameters (measurements/observations) which may 
be continuous or categorical variables or regression models (prediction). If the 
classification of each case is used as an input at the learning stage, the process is 
termed “supervised” learning, whereas if the classification is not used as an input, 
learning is “unsupervised”. 
A range of machine learning algorithms exist, each with certain advantages and 
disadvantages dependent on the type of problem. For this thesis, the discussion will 
be limited to Expectation Maximisation (EM) learning (Lauritzen 1995), a maximum 
likelihood method. An algorithm for EM learning is available in the Hugin software. 
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The learning process proceeds as follows. The CPN constructor specifies which 
conditional probability tables should be learned: this may be any or all tables and/or 
parts thereof. It is also possible to enforce zeros in conditional probability tables to 
define impossibilities. Following the specification of what is to be learned, the EM 
algorithm begins to iterate. The algorithm maximises the likelihood of all cases, 
calculated as the product of the joint probability of the data for each case. In Hugin, 
the algorithm terminates either when the specified maximum number of iterations is 
reached or the tolerance for the difference in log-likelihood between two successive 
iterations is reached. 
If all of the nodes in a CPN are observed, and these observations are recorded in the 
case data for learning, the learning process degenerates to counting and becomes 
trivial. However, this is not the case for the sepsis model. The sepsis CPN contains 
several latent (unobservable) variables which is an added difficulty where learning is 
concerned. This is coupled with the fact that medical/clinical databases are typically 
plagued by missing data; not every patient receives the same tests. 
2.3. THE TREAT MODEL OF INFECTION 
The Treat CPN was constructed via a semi-formal approach, using the literature, 
expert opinion and patient data to specify the conditional probability tables. The 
success of this technique has been demonstrated empirically through the success of 
Treat (Kristensen et al. 1999, Paul et al. 2006b, Leibovici, Paul & Andreassen 2010, 
Kofoed et al. 2009). The Treat CPN, shown in Figure 2.5, is very large, containing 
approximately 6000 nodes. Within the CPN, eleven sites of infection are modelled, 
each with local symptoms and findings and a set of relevant pathogens. One small 
section of Treat describes the inflammatory response: the Sepsis CPN, highlighted in 
Figure 2.5. Treat is specifically designed to account for geographical, demographical 
and other hospital-specific differences in pathogen prevalence and resistance to 
antimicrobials; it is calibrated to each specific hospital as part of the installation 
process. 
Treat’s advantage over clinicians is due to the ability of the CPN to hold knowledge 
in the form of large arrays of conditional probability tables and to handle complex 
probability calculus. The prescription of empirical antibiotic treatment involves a set 
of decision points which the clinician must go through. First, the clinician must 
decide whether the patient has an infection, and if so, where the infection is focused. 
Based on the likely focus of infection, the clinician must then decide what the most 
likely causative pathogen is. Given the most probable pathogen, which treatment 
offers the best balance of coverage (dependent on local resistance patterns), potential 
side-effects and cost? Empirical antimicrobial prescribing is not a trivial task, it 
involves complex decision-making, and computerised decision support tools may be 
able to improve the practice (Leibovici et al. 1999). The set of decisions made when 
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prescribing antimicrobials can be equated to the multiplication of large conditional 
probability matrices, which is not a task that humans excel at. 
 
Figure 2.5: The Treat CPN. The structure of the CPN is divided into 11 sites of infection, 
where the base units are pathogens. One small part of the network, the Sepsis CPN 
(highlighted), deals with the inflammatory response. 
Treat has been described extensively in the literature, from the original concept 
(Andreassen et al. 1999, Leibovici et al. 2000), through its development into a tool 
suitable for research (Andreassen et al. 2005) to the results achieved through clinical 
trials of the system (Paul et al. 2006b, Paul et al. 2006a, Paul et al. 2007, Leibovici 
et al. 2007, Leibovici, Paul & Andreassen 2010). Treat was developed collaboratively 
by researchers at Aalborg University (AAU) and Rabin Medical Centre, Israel as part 
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of an EU funded project (EU 5th framework, Information Society Technologies, 
contract no.: IST-9999-11459) The stochastic model of infection shown in Figure 2.5 
is combined with decision theory to provide advice that seeks to maximize the 
probability of effective treatment while minimizing both the direct cost of the 
treatment as well as the ecological cost of furthering antimicrobial resistance and any 
side effects that may occur. 
In an observational trial run in three major European hospitals, Treat showed great 
improvements versus clinician-only regimes, improving covering antibiotic 
treatment from 57% to 70% (Paul et al. 2006b). Treat also showed improvements 
when used in a cluster-randomized interventional trial with appropriate empirical 
antibiotic treatment in 73% of cases in interventional wards compared with 64% in 
control wards (Paul et al. 2006b). Long-term (6 month) survival was also higher in 
interventional wards, and even higher in cases where Treat’s recommendations were 
followed (Leibovici, Kariv & Paul 2013). 
2.4. SEPSIS: THE MODELLER’S PERSPECTIVE 
This section uses Treat’s Sepsis CPN to explain sepsis from a modelling point of 
view, describing its construction. To build a causal model, it is necessary to 
understand the pathogenesis and pathophysiology of sepsis, and how this can be 
recognised in terms of measureable variables such as clinical chemistry, blood gases, 
haematology, etc. Section 2.4.1 describes what happens to a patient during sepsis in 
terms of the physiological changes typically seen in sepsis patients. The variables 
used by the Sepsis CPN and their links to sepsis pathophysiology are also described. 
Section 2.4.2 describes how CPN models can be used to describe a patient’s 
condition, defining the conditional probability tables linking the model parameters 
and patient condition. This step can also be thought of as the development of a 
composite biomarker. 
2.4.1. WHAT HAPPENS TO A PATIENT DURING SEPSIS 
The response to an infection depends on the severity of the disease, as well as other 
host-specific factors: comorbidities and immune-status modifiers 
(immunosuppressant drugs etc.). The SIRS criteria are present in most patients as 
they are part of the general response to infection. Increasing severity of sepsis is 
generally associated with a greater degree of organ dysfunction and/or failure. Figure 
2.7 describes some of physiological alterations seen in sepsis: all major organ systems 
are involved. Inflammatory variables shown in the white box are common 
manifestations of sepsis that are not linked to any organ damage specifically. 
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Figure 2.7: Physiological changes seen during sepsis according to the 2001 International 
Sepsis Definitions Conference (Levy et al. 2003). Sepsis patients may present with some or 
all of these. 
Table 2.1: Treat infection variables and their relation to sepsis pathophysiology and sepsis 
severity. + designates higher values and - designates lower values of the variables.* 
designates significant predictor (p<0.05) 
Infection Variable 
(units) 
Change in the variable for given severity Predictive Ability (AUC) 
Mild Moderate Severe Critical Bacteraemia 
30-day 
Mortality 
Temperature (°C) -/+ ++ ++ ++ or -- 0.62* 0.48 
Heart rate(beats/min) ++ ++ ++ ++ 0.59* 0.54* 
Respiratory rate 
(breaths/min) 
+ ++ ++ +++ 0.52 0.63* 
Leukocytes  
(cells/mm3) 
+ ++ ++ ++ or -- 0.53 0.56* 
Creatinine (mg/dl) + + ++ +++ 0.61* 0.59* 
Albumin (g/l) - -- --- ---- 0.63* 0.72* 
CRP (mg/l) + +++ +++ ++++ 0.63* 0.45 
Lactate (mmol/l) -/+ -/+ + ++ 0.67* 0.54 
Mental-status -/+ - - --   
Blood pressure 
(mmHg) 
-/+ -/+ - --- 0.57* 0.57* 
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Table 2.1 takes a detailed look at a selection of the variables noted in Figure 2.7: 
those used in the Sepsis CPN, and their association with sepsis. The choice of 
variables was based on availability of measurements/recorded data in available 
patient databases as well as expert opinion regarding the variables involved in the 
systemic response to infection. For each variable, + and – indicate that higher- or 
lower values, respectively, are associated with given sepsis severities. The changes 
in each variable given sepsis severity are based on those in the Treat Sepsis CPN. 
The predictive ability is measured by the area under the ROC curve (AUC). An AUC 
= 0.5 is indicative of no discrimination and AUC = 1 is perfect discrimination. To 
compute the AUC, it was assumed that a higher value of the variable would predict 
bacteraemia and 30-day mortality, with the exception of albumin and systolic blood 
pressure, where the opposite was assumed. The dataset used consists of 3589 patient 
cases collected during trials of Treat at Beilinson Hospital, Petah Tiqva, Israel, 
between 2004 and 2011. The dataset is described further in Chapter 4. 
After identifying candidate model variables, it is necessary to specify the model 
structure. The simplest version of a CPN is the so-called “naive Bayes” model, where 
all of the effects are directly linked to one cause, as shown in Figure 2.8. However, 
“naive Bayes” requires that all of the variables are independent, which is not the case 
for many of the sepsis variables. The original constructors of the Sepsis CPN got 
around this problem by performing a factor analysis – a dimensional reduction 
technique – to group the observable parameters beneath a set of statistically 
constructed independent factors (Leibovici et al. 2000). The result was four 
intermediate factors that described 80% of the variation in the data. The model 
 
Figure 2.8 ”Naive Bayes” model of a disease 
structure is shown in Figure 2.9.It was speculated that these factors may have physical 
analogues – when the same method was used on a set of data including inflammatory 
mediators, it was found that interleukin 6 (IL-6) had a loading of 0.91 on ‘fever 
factor’ – fever factor could be renamed IL-6 and given real units, and tumour necrosis 
factor alpha (TNF-α) had a loading of 0.50 on ‘shock factor’ – i.e. it is a major cause 
of shock factor (Leibovici et al. 2000). The correlation with real physical parameters 
provides further validation of the technique. 
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Figure 2.9: Structure of Treat’s sepsis CPN. Sepsis (red) causes changes in the set of 
observable parameters (green nodes) through four intermediate factors: ’Fever_factor’, 
’Alb_factor’, ’Leuko_factor’ and ’Shock_factor’ (yellow nodes). 
2.4.2. DESCRIBING THE PATIENT’S CONDITION 
We want to express the severity of a patient’s sepsis on a scale from no sepsis to 
critical sepsis. To do this, we need to make a mathematical description of how each 
of the infection variables in the Sepsis CPN behave according to the severity of 
sepsis. The construction of the CPN model takes therefore a top-down approach, 
asking, for example: given that a patient has moderate sepsis, what is their 
temperature? The temperature of the ‘patient’ is then expressed as a probability 
distribution. This probability distribution may be continuous Gaussian distributions 
or discrete distributions, the latter was used in the original Sepsis CPN. 
Table 2.1 is constructed from a combination of literature knowledge and expert 
opinion. Finding the numbers to complete the construction of the CPN can then be 
seen as the conversion of Table 2.1 to a set of conditional probability tables. For 
patients with no sepsis, it is assumed that they will fall within the normal range. 
The construction of the sepsis CPN is completed by translating the knowledge 
contained in Table 2.1 into conditional probability tables. In the original Treat sepsis 
network, the factor nodes had three states: no, moderate and severe. Figure 2.10 uses 
temperature as an example to show how these distributions look for each state of 
sepsis. In addition to the no sepsis group, the former Treat sepsis CPN recognised 
four severity groups for bacterial sepsis: mild, moderate, severe and critical. The 
green bars and the numbers next to them reflect the probability of a patient having a 
temperature in the specified range, given that they have the degree of sepsis 
highlighted by the red bar. As expected from Table 2.1, there is little distinction 
between the temperature distributions for moderate, severe and critical sepsis, but 
they are all significantly different to the no sepsis group. 
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Figure 2.10: Distribution of temperature (fever) for patients with, from left to right, no; 
moderate; severe; and critical sepsis. The red bars highlight the given severity of sepsis and 
the green bars represent the respective probability distributions across the temperature 
groups. 
Once the specification of the conditional probability tables is complete, the CPN can 
be compiled and used. An example of the CPN in use is shown in Figure 2.11. The 
evidence entered into the model is given by the black text below the nodes. The 
monitor windows show the inferred probabilities. It is possible to see that each of the 
“factor nodes” can be activated differently; in this case “Leuko_factor” has more 
severe evidence entered into its children, showing almost 50% probability of the state 
“severe”, much higher than that observed for “Alb_factor” and “Fever_factor”. The 
children of “Shock” are all set to no or normal, resulting in the probability of “Shock” 
less than 0.001%. The combined evidence is used to infer that the patient most likely 
has “moderate” sepsis. 
 
 
Figure 2.11: The Treat sepsis CPN in use. Evidence entered is shown by the text beneath the 
nodes, and monitor windows are opened to show the inferred probabilities. Figure adapted 
from (Andreassen et al. 2005). 
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CHAPTER 3. MANUAL LEARNING: 
DEVELOPMENT OF CONTINUOUS 
DISTRIBUTIONS 
This chapter is based on Paper I, entitled “A Bayesian Approach to Model 
Development: Design of Continuous Distributions for Infection Variables”. This 
paper described the process of updating the Treat Sepsis CPN, subsequently referred 
to as the discrete sepsis or D-Sepsis CPN, to the continuous sepsis or C-Sepsis CPN. 
This “manual learning” process represents the first stage of the PhD project’s model 
development stage, highlighted in Figure 3.1. 
 
Figure 3.1 Sepsis CPN development framework. Dark blue boxes represent the stages of 
model development for the Sepsis CPN, other boxes represent the inputs to each construction 
or learning phase. This chapter describes the highlighted section: the development of the C-
Sepsis CPN from the D-Sepsis CPN. 
The aim of constructing the C-Sepsis CPN was to improve the performance of Treat 
and remove some of the undesirable behaviour associated with discrete nodes. 
”Jumping” in the assessment of the patient state was one such behaviour: the 
discretization of temperature meant that an increase from 38.6 °C to 38.7 °C could 
result in a large jump in the assessed illness severity, while an increase from 38.5 °C 
to 38.6 °C led to no change. 
The distributions for each infection variable were learned manually via a semi-formal 
process where the discrete variables in the D-Sepsis CPN were converted to 
continuous variables and revised based mainly on expert opinions and the literature. 
In the C-Sepsis CPN, each infection variable is described as a normal- or log-normal 
distribution for five illness severities termed no, mild, moderate, severe and critical. 
A literature search was conducted for each infection variable; some variables were 
well reported in the literature as they have been researched as sepsis biomarkers while 
others had little literature available. To describe the process of defining continuous 
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variables we looked at two examples, one for which much literature is available, CRP, 
and one for which little is available, albumin. 
For CRP, the literature search returned 1654 studies, of which 20 were relevant and 
of sufficient quality to conduct a meta-analysis. The meta-analysis involved grouping 
patients according to the severity of their illness, and the aetiology (infectious/non-
infectious). In all, nine classifications were used: 4 infectious; viral infection, sepsis, 
severe sepsis and septic shock, and 5 non-infectious; healthy, no SIRS (patients who 
may be ill but do not meet the SIRS criteria), SIRS, severe SIRS and non-septic 
shock. A pooled, log-normal distribution was calculated for each of the nine 
classifications, the result of which was the 9 distributions shown in Figure 3.2. 
 
Figure 3.2 Log-normal distributions for 4 infectious (top panel) and 5 non-infectious (bottom 
panel) patient groups. Individual distributions are the result of meta-analysis of literature 
studies. Figure from Paper I (Ward et al. 2014). 
The distributions described in Figure 3.2 were formed based on literature definitions 
of sepsis and SIRS patients, and must therefore be mapped to the five illness 
severities used in the C-Sepsis CPN. The C-Sepsis CPN distributions shown in Figure 
3.3 were defined after input from experts, the details of how this was done are 
described in Paper I. 
A similar literature search was conducted for albumin, however none of the 244 
resulting papers were suitable for defining explicit distributions for albumin stratified 
by sepsis severity and/or aetiology. The impossibility of a meta-analysis meant that 
sepsis/SIRS severity-based distributions for albumin must be designed in a different 
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Figure 3.3 Transformation of the normal distributions from the meta-analysis (left) to the C-
Sepsis distributions (right). Figure from Paper I (Ward et al. 2014). 
way. The discrete distributions used in the D-Sepsis CPN were used along with data 
from the Treat study (Paul et al. 2006b) to set the range to be covered by the set of 
distributions. Literature was available to define a distribution for the ”no” severity; 
the distribution was taken from a large study of albumin as a predictor of mortality 
(Corti et al. 1994). Albumin is also a concentration-dependent predictor of poor 
outcome (Vincent et al. 2003), with low albumin being correlated with high severity. 
The distributions implemented in the C-Sepsis CPN are shown in Figure 3.4. 
 
Figure 3.4 C-Sepsis distributions for Albumin. Figure from Paper I (Ward et al. 2014). 
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As a validation step, the predictive abilities of the D-Sepsis and C-Sepsis CPNs were 
compared. The Treat CPN, in addition to providing treatment advice, can be used to 
make a prediction of the probability of bacteraemia. The data used was collected from 
263 patients suspected of infection in the acute ward at Hvidovre Hospital, 
Copenhagen University Hospital, Denmark from November 2011 to May 2012. Of 
the included patients, 19 (7.2%) had bacteraemia. 
The predictive ability of each model (Treat with the D-Sepsis CPN, Treat with the C-
Sepsis CPN) was assessed using the area under the ROC curve (AUC): greater area 
under the curve means better predictive ability. The AUC for the C-Sepsis CPN 
model was 0.80 (95% Confidence interval (CI) 0.70-0.90) while the AUC for the D-
Sepsis CPN model was 0.73 (95% CI 0.62-0.85). The two curves are shown overlaid 
in Figure 3.5. The difference between the two curves was not statistically significant 
(p=0.3), however it suggests that the manual construction of continuous nodes in the 
Treat sepsis CPN can improve the prediction of bacteraemia. This result provided 
motivation for further testing using a larger database, and further development of the 
model through the application of automatic learning methods to adjust the prior 
probability distributions. In subsequent use of the C-Sepsis model, other issues were 
noted such as extremely large odds ratios when approaching the upper- and/or lower 
limits of the physiological range for some of the infection variables, notably CRP. 
 
Figure 3.5 ROC curves for bacteraemia prediction for Treat with the D-Sepsis and C-Sepsis 
CPNs. Figure from Paper I (Ward et al. 2014).
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CHAPTER 4. AUTOMATIC LEARNING: 
MODEL TUNING TO IMPROVE 
PREDICTIVE PERFORMANCE 
Following the manual learning described in Chapter 3, the C-Sepsis CPN was 
transformed into a Learned Sepsis CPN as described by the highlighted section of 
the model-development framework in Figure 4.1. This chapter is based on Papers II 
and III, which describe the steps taken to tune the C-Sepsis CPN to predict 30-day 
mortality, with the results being the L-Sepsis CPN (Paper II) and the LA-Sepsis CPN 
(Paper III).  Using a similar learning strategy, the C-Sepsis CPN was also tuned to 
predict bacteraemia, forming a standalone “SepsisFinder” model. 
 
Figure 4.1 Sepsis CPN development framework. Dark blue boxes represent iterations of the 
Sepsis CPN, the other boxes represent the inputs to each construction or learning phase. 
This chapter describes the highlighted section: the development of the L-Sepsis CPN from the 
C-Sepsis CPN. 
The C-Sepsis CPN removed the undesirable behaviours of the D-Sepsis CPN, such 
as jumps in the assessment of the patient state in response to small changes in the 
input variables. Validation using a small dataset (263 patients) showed a non-
significant improvement over the D-Sepsis CPN for the prediction of bacteraemia. 
However, other undesirable behaviours were noticed, such as excessively large odds-
ratios in patients who presented with values of infection variables in ranges that 
weren’t suitably covered by the continuous distributions. The aim of automatic 
learning was to improve the predictive performance of the network. 
The data material used for learning was taken from a set of patient data collected 
during trials and/or studies of the Treat system (Andreassen et al. 2005, Paul et al. 
2006b) at Beilinson Hospital, Rabin Medical Centre in the period from 2004-2011. 
Patients were included in the studies based on suspicion of infection which included 
those for whom blood was drawn for culture, those receiving antimicrobials not for 
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prophylaxis, those with SIRS and those with a clinically identified focus of infection 
(Paul et al. 2006b). The data included information on infection variables such as the 
patients’ vital parameters, clinical chemistry and blood gases, empirically prescribed 
treatments, the results of blood and other cultures including in vitro susceptibility 
testing, 30-day mortality, and a final clinical diagnosis. The diagnosis allowed 
patients to be divided into infectious- and non-infectious groups: data were available 
for 3589 patients, of whom 2855 had a confirmed infectious or non-infectious 
diagnosis. The infectious diagnoses also allowed sub-groups to be defined for 
different sites of infection, for example lower respiratory tract or urinary tract 
infections. The remaining 734 patients had an unknown or uncertain final diagnosis. 
The EM learning algorithm offered by Hugin was used to learn the LA-Sepsis CPN 
(Section 2.2.2). The previous semi-formal “manual” learning process connected 
continuous distributions to literature defined sepsis severities: sepsis, severe sepsis 
and septic shock, which were then related to our own severity states: no, mild, 
moderate, severe and critical. Automatic learning from data allows us to move a step 
further away from the literature distributions and relate our sepsis severity states 
directly to patient mortality. This represents an important step in the development of 
the LA-Sepsis CPN. 
 
Figure 4.2 The LA-Sepsis CPN structure, figure from Paper III. Nodes are represented by 
ovals, causal links by arrows. Causality is expressed through conditional probability tables. 
The nodes with double rings represent stochastic variables with continuous probability 
distributions. The remaining nodes have discrete probability distributions.  NSIRS is the non-
infectious systemic inflammatory response syndrome. Nodes not learned are shown in blue. 
The structure of the LA-Sepsis CPN is shown in Figure 4.2 Three potential causes for 
death are given: NSIRS, sepsis and background, where background represents all 
other causes. NSIRS and sepsis are assumed to have the same mortality rates for a 
given illness severity (Vincent et al. 2006, Dulhunty et al. 2008). Mortality rates are 
loosely based on the pneumonia severity index (PSI) (Fine et al. 1997) in combination 
with the sepsis literature, where the latter is used to define the mortality rates for 
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severe and critical sepsis. The mortality rates used are 0%, 1%, 8%, 45% and 75% 
for no, mild, moderate, severe and critical, respectively. 
 
Figure 4.3 An example of initial specified distributions (A) and learned composite 
distributions (B) for one of the variables in the sepsis CPN: albumin. Each of the 
distributions in Panel B is a linear combination of the distributions in Panel A. Figure from 
Paper II (Ward, Andreassen 2015). 
Figure 4.3 shows the result of automatic learning for one of the infection variables: 
albumin. A set of normal distributions, covering the physiological range observed in 
the patient data, was generated for each variable. Panel A shows these distributions 
for albumin. Through the EM learning process composite curves are learned for each 
severity state by learning the tables for the “factor-mapping” nodes (yellow in Figure 
4.2). The resulting curves, shown in Panel B, are linear combinations of the curves 
in Panel A. As noted in Chapter 3, albumin is a concentration-dependent predictor of 
outcome, which is confirmed here: the more severe states are associated with lower 
GRADATION OF THE SEVERITY OF SEPSIS 
36
 
albumin, although the differences between the mild/moderate and severe/critical 
distributions are minimal. 
Another feature introduced in the C-Sepsis CPN was the possibility to differentiate 
between NSIRS and sepsis. During automatic learning, the links between the NSIRS 
severities and the four sepsis factors are learned (Figure 4.2: yellow nodes). Each 
factor can be considered a branch of the immune system, as suggested by the factors’ 
correlation with inflammatory mediators (Section 2.4.1). Each branch may be 
activated differently according the aetiology of inflammation, i.e. infectious or non-
infectious. Panel A of Figure 4.4 shows the difference in temperature for sepsis = 
moderate and NSIRS = moderate. Patients with the infectious aetiology (sepsis) 
present with a higher fever than those without infection (NSIRS) for a given severity 
of illness. For variables that do not differentiate between infection and no infection, 
such as systolic blood pressure (Figure 4.4 Panel B), no such difference is seen. 
 
Figure 4.4 Conditional probability distribution for temperature (panel A) and systolic blood 
pressure (panel B) for Sepsis and NISIRS patients with severity = moderate. Figure from 
Paper III. 
The area under the ROC curve is used to assess the ability of each model to predict 
30-day mortality. Figure 4.5 shows ROC curves for the C-Sepsis, L-Sepsis and LA-
Sepsis CPNs. The AUCs for the C-, L- and LA-Sepsis CPNs were 0.65, 0.74, and 0.79 
respectively. Each improvement (C- to L-, L- to LA-) was also statistically significant 
(p=10-8, p=0.0004 respectively). To guard against overfitting, cross-validation was 
also carried out as part of the development of the L- and LA-Sepsis CPNs, this is 
described in further detail in Papers II and III. 
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Figure 4.5 ROC curves for the prediction of 30-day mortality for the C-Sepsis, L-Sepsis and 
LA-Sepsis CPNs. Figure from Paper III. 
In a clinical setting, patients may be graded by a clinical score such as SIRS or 
mREMS (modified Rapid Emergency Medicine Score) (Olsson, Terént & Lind 2004, 
Howell et al. 2007). Both SIRS and mREMS could be calculated for only 708 patients 
(25% of all patients). The 30-day mortality for these patients was 9.9%. Another 
score, the MEDS (Mortality in Emergency Department Sepsis) score (Shapiro et al. 
2003), could not be calculated given the available patient data. Figure 4.6 shows ROC 
curves for the prediction of 30-day mortality for the LA-Sepsis CPN, mREMS and 
SIRS scores. The LA-Sepsis CPNs prediction of 30-day mortality outperforms the 
SIRS and mREMS scores. The AUC of the LA-Sepsis CPN also compares well with 
the reported performance of MEDS, where the AUC ranged from 0.75-0.88 
(Carpenter et al. 2009). The low number of patients for whom the clinical scores 
could be calculated underlines the advantage offered by CPNs with their ability to 
handle missing data. 
In addition to the discriminative ability assessed by the ROC curve, calibration is 
assessed by the Hosmer-Lemeshow statistic. Figure 4.7 shows the calibration curve 
for the LA-Sepsis CPN. Perfect calibration is seen on the curve as a straight y=x line, 
i.e. predictions match the observations. A non-significant Hosmer-Lemeshow test 
result (p>0.05) signifies that the model is well calibrated. The LA-Sepsis CPN is 
therefore a well-calibrated model. 
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Figure 4.6 ROC curves for the prediction of 30-day mortality for the LA-Sepsis CPN, and the 
SIRS and mREMS scores. 
 
Figure 4.7 Hosmer-Lemeshow calibration curve for the prediction of 30-day mortality using 
the LA-Sepsis CPN. Figure from Paper III. 
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Despite the model being well-calibrated overall, we noted some differences in 
calibration when conducting a sub-group analysis. Figure 4.8 shows regression lines 
for patients in the two most prevalent infection sites: lower respiratory tract (LRT) 
infections and urinary tract infections (UTI). There were 697 LRT infections with 
128 deaths and 486 UTIs with 41 deaths. The gradients of the regression lines in 
Figure 4.8 show that for a given severity of the immune response, an LRT infection 
is more likely to lead to death. This trend was visible for both the L-Sepsis and LA-
Sepsis CPNs. 
Prior to the LA-Sepsis CPN, the Sepsis CPNs were limited to describing the 
manifestations of sepsis and NSIRS. Risk factors are commonly included in clinical 
scores such as MEDS. The inclusion of age as a risk-factor in the LA-Sepsis CPN 
resulted in a significant improvement in the prediction of 30-day mortality compared 
to the L-Sepsis CPN. Reintegration within Treat means including a range of other 
risk factors, including but not limited to comorbidities and the site of infection. The 
difference between UTI and LRT infections shown in Figure 4.8 suggest that 
knowledge of the site of infection has the potential to further improve the predictive 
performance. 
 
Figure 4.8 Regression lines for the observed 30-day mortality vs. the LA-Sepsis CPN’s 
predicted 30-day mortality for all 2855 patients (black), 697 patients with a lower 
respiratory tract infection (red) and 486 patients with a urinary tract infection (green). 
Figure from Paper III. 
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Using a similar learning strategy, the C-Sepsis CPN was also tuned to predict 
bacteraemia, with the result being the “SepsisFinder” model (unpublished). The same 
2855 patient cohort was used for the validation of both the LA-Sepsis CPN and 
Sepsisfinder. There were 309 patients (10.8%) with bacteraemia. Using SepsisFinder 
as a standalone model (not integrated within Treat), the AUC for the prediction of 
bacteraemia was 0.74 (95% CI 0.71-0.76). Figure 4.9 shows ROC curves for the 2885 
patients from Beilinson Hospital, along with curves for the prediction of bacteraemia 
in two cohorts of Danish patients: 263 patients including 19 (7.2%) with bacteraemia 
from Hvidovre Hospital (HvH) and 199 patients including 11 (5.5%) with 
bacteraemia from Sygehus Lillebælt (SLB). The AUC for SepsisFinder’s prediction 
of bacteraemia was 0.74 (95% CI 0.63-0.85) for the HvH patients and 0.79 (95% CI 
0.67-0.92) for the SLB patients. SepsisFinder’s stable performance across the three 
cohorts suggests that it may not require calibration for local conditions; the response 
to sepsis is demographically and geographically invariant. 
 
Figure 4.9 ROC curves for the prediction of bacteraemia using the SepsisFinder model on 
three cohorts of patients: n=2885 patients from Beilinson Hospital, n=263 patients from 
Hvidovre Hospital (HvH) and n=199 patients from Sygehus Lillebælt (SLB).
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CHAPTER 5. APPLICATIONS OF 
SEPSISFINDER 
This chapter is in part based on Paper IV, which describes one application of the 
SepsisFinder model described in Chapter 4: identifying candidates for rapid-
diagnostic testing through risk-based stratification of patients suspected of infection. 
This application represents the final stage of the PhD project, an overview of which 
is shown in Figure 5.1. 
 
Figure 5.1 PhD project framework. This chapter is associated with the highlighted section: 
Applications. 
Chapter 3 and Chapter 4 described the construction of the C-Sepsis CPN and the L- 
and LA-Sepsis CPNs and SepsisFinder, through the manual construction to automatic 
learning to tune the CPN. Chapter 4 described tuning the model to predict 30-day 
mortality, and the use of the same technique to tune the SepsisFinder model to predict 
bacteraemia. The prediction of bacteraemia has significant commercial potential: 
rapid diagnostic methods can identify the causative pathogen in sepsis patients much 
faster than blood culture, however they are also much more expensive. Identifying a 
group of “high-risk” patients where the probability of a positive test is higher has the 
potential to increase the cost-effectiveness of these tests. In paper IV, PCR testing 
was used as an example to illustrate this principle. 
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We assumed that the added value of a PCR test is defined for the incremental increase 
in the number of patients receiving appropriate treatment, due to the identification of 
pathogens via PCR. This value is realized as a reduction in mortality: the odds ratio 
for 30-day mortality for patients receiving inappropriate empiric treatment against 
those receiving appropriate treatment is approximately 1.60 (Paul et al. 2010). We 
measure cost-effectiveness relative to standard clinical practice (blood culture alone), 
with the costs being the total healthcare costs and the effect being the incremental 
reduction in mortality. The cost-effectiveness is assessed by the incremental cost-
effectiveness ratio (ICER) in terms of euros (€) per life-year saved. The ICER is 
defined in Equation 5.1. The difference in total healthcare costs, Δcost, is 
approximated by the two largest contributors: PCR testing, where nPCR is the number 
of tests conducted and costPCR = €300 (Lehmann et al. 2010, Alvarez et al. 2012) is 
the cost per test, and the cost of hospitalisation, where nA,add is the additional number 
of patients receiving appropriate treatment, ΔLOS is the difference in length of stay 
(in days) for patients receiving appropriate and inappropriate treatment and costbed is 
the cost of a bed-day. The incremental effectiveness is measured in terms of the 
number of life-years saved, where nsurv is the incremental number of survivors and 
LYsurv = 5.43 years (Lehmann et al. 2010) is the number of life-years saved per 
survivor. 
ICER=
∆𝑐𝑜𝑠𝑡
∆LY
=
𝑛𝑃𝐶𝑅𝑐𝑜𝑠𝑡𝑃𝐶𝑅−𝑛𝐴,𝑎𝑑𝑑∆𝐿𝑂𝑆𝑐𝑜𝑠𝑡𝑏𝑒𝑑
𝑛𝑠𝑢𝑟𝑣𝐿𝑌𝑠𝑢𝑟𝑣
                    (5.1) 
The data material for the assessment was the 3589 patients described in Chapter 4. 
Of these patients, 377 had true-positive bacteraemia. True-positive bacteraemia is 
defined by positive blood culture of a pathogen determined to be clinically 
significant. The significance of the pathogens found by blood culture was assessed 
by Treat, Coagulase negative staphylococci, bacillus sp., corynebacteria sp., 
bacteroides sp. and anaerobic gram-positive rods were all considered non-significant 
isolates. 
The cost-effectiveness analysis used a combination of findings from the dataset along 
with figures from the literature, with the two being compared where possible. In 
Figure 5.2 the high-risk group was selected as those patients with model predicted 
probability of bacteraemia, pBC+, greater than a given threshold PBC+ > 20%. The high-
risk group consisted of n = 700 patients and the fraction of these patients with positive 
blood culture, fBC+, was 23.9%. The ICER for the high-risk group was €6,934 (95% 
CI €3,669 - €12,484) per life-year and €24,056 (95% CI €15,936 – €38,959) per life-
year for the complementary low-risk group. Confidence intervals were calculated for 
a 10,000 trial Monte-Carlo sensitivity analysis wherein all parameters in the cost-
effectiveness model were varied independently according to their underlying 
statistical distributions. 
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Figure 5.2 Figure from Paper IV. Calculation of the ICER - value is added for the 
incremental increase in the number of patients receiving appropriate treatment due to the 
pathogen being identified by PCR 
The sensitivity to the model’s selection of a high-risk group was assessed by 
repeating the cost-effectiveness analysis for a range of thresholds, PBC+, from 0% to 
35% in steps of 2.5%. Table 5.1 presents the median ICER for the low- and high-risk 
group for each threshold, PBC+. When the threshold was removed, the ICER was 
€16,774 per life-year. The ICER in the high-risk group ranged down to €1,353 per 
life-year for PBC+ = 32.5%, while the ICER in the low-risk group reached a maximum 
of €534,355 per life-year when PBC+ = 2.5%. 
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Table 5.1: ICERs for complementary low- and high-risk groups for thresholds, PBC+, ranging 
from 0% to 35% in steps of 2.5% 
Threshold, 
PBC+ (%) 
nlow-risk  
(%) 
ICERlow-risk  
(€/life-year) 
nhigh-risk 
(%) 
ICERhigh-risk  
(€/life-year) 
0 0 (0.0) - 3589 (100.0) 16774 
2.5 736 (20.5) 534355 2853 (79.5) 12606 
5.0 1237 (34.5) 158789 2352 (65.5) 10423 
7.5 1734 (48.3) 71570 1855 (51.7) 8906 
10.0 2081 (58.0) 42017 1508 (42.0) 8553 
12.5 2349 (65.5) 32920 1239 (34.5) 7177 
15.0 2546 (70.9) 29870 1043 (29.1) 7735 
17.5 2723 (75.9) 27768 866 (24.1) 6775 
20.0 2889 (80.5) 24056 700 (19.5) 6934 
22.5 3074 (85.7) 21367 515 (14.3) 7090 
25.0 3309 (92.2) 20845 280 (7.8) 4281 
27.5 3471 (96.7) 18815 118 (3.3) 2653 
30.0 3541 (98.7) 17528 48 (1.3) 2353 
32.5 3582 (99.8) 16924 7 (0.2) 1353 
35.0 3589 (100.0) 16774 0 (0.0) - 
 
Figure 5.3 presents the results of the Monte-Carlo analyses for the full range of PBC+. 
Panel A shows the results for the high-risk group, and Panel B the results for the 
complementary low-risk group. A threshold of PBC+ = 0% meant that all patients were 
assigned to the high-risk group and a threshold of PBC+ = 35% meant that all patients 
were assigned to the low-risk group. The threshold for cost-effectiveness defined by 
the National Institute for Clinical Excellence (NICE) (Appleby, Devlin & Parkin 
2007) is £20,000 to £30,000 (about €35,000, shown as a dashed line in both panels). 
When looking at the high-risk group alone, cost-effectiveness is demonstrated 
(according to NICE) even when the threshold is removed: the ICER for all patients 
is €16,774 per life-year which is significantly lower than the cost-effectiveness 
threshold of €35,000 per life year. However, this result does not tell the full story. By 
removing the threshold we are including a large number of low-risk patients for 
testing. We may instead choose our high-risk group by removing those patients for 
whom PCR testing is not cost-effective. At a threshold of PBC+ = 10.0%, the patients 
(58.0% of all patients) below this threshold have an ICER = €42,017 per life-year 
saved. For these patients, PCR testing is not cost-effective. If the high-risk group is 
taken as all patients above this threshold, the ICER is €8,553 per life-year.  
In addition to the ICER, hospitals must also consider other practical factors when 
choosing to run a test. The absolute cost is important along with the throughput of 
the laboratories running the test: it may be simply impractical to run PCR tests on 
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every patient suspected of infection. So although we have found that it is not cost-
effective to run PCR for patients below a threshold of PBC+ = 10.0%, this threshold 
does not necessarily define the choice of “high-risk” patients for whom testing should 
be done. If the number of patients being tested is limited by laboratory throughput, 
the threshold for “high-risk” will be set higher. Raising the threshold further will have 
the dual effect of reducing the number of tests and increasing the incremental benefit 
of each test, seen as the ICER falling with increasing threshold. 
 
Figure 5.3 Figure from Paper IV. Boxplot for the Monte-Carlo analysis repeated at cut-offs 
of PBC+ = 0% to 35% in steps of 2.5%. Panel A shows the results for the high-risk group and 
Panel B for the low-risk group. 
Risk-based stratification can be used to improve the cost-effectiveness of PCR by 
removing patients for whom PCR testing is not cost-effective. PCR in an inpatient 
population also provides an opportunity to increase appropriate treatment rates in the 
highest-risk patients before they are transferred to the ICU, perhaps even preventing 
ICU admissions.
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CHAPTER 6. DISCUSSION 
This chapter discusses the significance of the work completed during the PhD project 
and offers suggestions for the direction of future work.  
6.1. MAIN FINDINGS 
Manual learning: Design of continuous distributions for infection variables 
Starting with the D-Sepsis CPN that was part of Treat, the first goal of the PhD project 
was to introduce continuous distributions for infection variables, forming the C-
Sepsis CPN. This was done manually, combining expert opinion with knowledge 
gleaned from the literature, a method that has been proven successful several times 
in CPN construction. The C-Sepsis CPN was validated by comparing the predictive 
ability of the C-Sepsis and D-Sepsis CPNs with the remainder of the Treat model 
being identical. The C-Sepsis CPN had an AUC of 0.80 for the prediction of 
bacteraemia and the AUC for the D-Sepsis CPN was 0.73. The C-Sepsis CPN 
represented a sizable improvement in predictive performance, although the small data 
material meant that the result was not statistically significant. In addition to the 
improvement in predictive performance, the introduction of continuous variables 
solved the problem of “jumping” seen in the D-Sepsis CPN, where the discretization 
of variables meant that, for example, a change in temperature of 0.1°C could result 
in a large jump in the assessed illness severity. 
Automatic learning: Tuning via automatic learning to improve predictive 
performance 
Despite its success, manual learning is limited in what can reasonably be achieved. 
The availability of data in the literature was sub-optimal for the majority of 
parameters. Additionally, the manual construction involved what was effectively 
single-variable analysis. Automatic learning provided a structured way to further 
improve the model, tuning it to predict clinical outcomes; either diagnostic (presence 
of bacteraemia) or prognostic (30-day mortality). 
To facilitate machine learning, the C-Sepsis CPN was clipped out of the Treat model, 
and tuned as a standalone entity. The C-Sepsis CPN also allows for discrimination 
between infectious and non-infectious inflammation: sepsis and NSIRS. The learning 
strategy allowed the model to learn the different effects of sepsis and NSIRS on 
individual branches of the inflammatory response. 
The L-/LA-Sepsis CPNs resulting from automatic learning were validated by testing 
their predictive ability for 30-day mortality. The learned CPNs substantially 
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outperformed both SIRS and the mREMS score: the AUC for 30-day mortality was 
0.81, 0.67 and 0.54 for the LA-Sepsis CPN, the mREMS score and SIRS, respectively. 
The comparison with clinical scores also highlighted one of the advantages of CPN 
models – their ability to handle missing data. For the patient group studied, SIRS and 
mREMS scores could be calculated for approximately 50% and 25% of the patients, 
respectively. Other scores such as SOFA or MEDS could not be calculated for these 
patients. 
The performance of the LA-Sepsis CPN as a standalone model for mortality 
prediction also motivated the tuning of another version of the Sepsis CPN to predict 
bacteraemia – SepsisFinder. SepsisFinder’s performance in the prediction of 
bacteraemia was stable across patients from both Denmark and Israel, suggesting that 
the Sepsis CPNs may not require calibration for local conditions, that is, the sepsis 
response is temporally, demographically and geographically invariant. This is 
empirical evidence for one of the tenets used in the construction of Treat: that some 
parts of the model require calibration, while other parts, including the Sepsis CPN, 
do not. 
The SepsisFinder and LA-Sepsis CPNs represent a significant step forward from 
Treat’s original D-Sepsis CPN. Both models (considered as standalone entities) have 
greater predictive performance than the Treat model for bacteraemia- and 30-day 
mortality prediction, while using significantly fewer variables. Another advantage of 
the SepsisFinder and LA-Sepsis CPNs is the ability to continually adjust and improve 
the models as more data becomes available. 
Applications: Risk-based stratification of patients to improve cost-effectiveness 
of rapid diagnostics 
It was assumed that SepsisFinder, a “lightweight” model tuned to predict 
bacteraemia, could be used to stratify patients into risk-groups, as has previously been 
done using Treat (Paul et al. 2006a). The SepsisFinder model uses up to 12 routinely 
collected variables as opposed to over 100 used by Treat. The AUC for the prediction 
of bacteraemia using the SepsisFinder model was 0.75, an improvement on the AUC 
of 0.70 reported for Treat on a similar cohort (Paul et al. 2006a). 
One of the opportunities for utilising such risk assessment is in tailoring the 
diagnostic workup of patients suspected of sepsis. Expensive diagnostics can be made 
cost-effective by limiting them to patients where 1) they will most likely be able to 
influence treatment and 2) the influence on the treatment will give most benefit. 
SepsisFinder can improve the cost-effectiveness of expensive rapid diagnostics by 
identifying patients for whom testing would not be cost-effective. In a cohort of 3589 
patients, SepsisFinder was able to select 58% of patients for whom PCR testing 
would not be cost-effective (ICER = €42000 per life-year). 
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If the predictive ability could be further improved, such a risk-assessment could even 
be able to guide treatment vs. no treatment without performing the expensive test. 
Biomarkers such as procalcitonin and CRP have been suggested as useful candidates 
for guiding treatment (van der Does et al. 2016). The SepsisFinder model as a whole 
outperforms any individual variable, including CRP, allowing us to think of 
SepsisFinder as an intelligent biomarker. The addition of procalcitonin or other 
biomarkers to SepsisFinder could potentially further improve the cost-effectiveness 
of PCR testing. 
6.2. FUTURE WORK 
The work described in this thesis will be continued as part of an Industrial PostDoc 
project; a collaboration between Treat Systems ApS and Aalborg University, partially 
funded by Innovationsfonden Danmark. Over a two year period it is expected that the 
risk-assessment model of SepsisFinder will be refined and tested clinically, while 
development begins on modules aimed at the early recognition of infection and 
revision of treatment in patients for whom infections are not microbiologically 
documented. In addition to work on the SepsisFinder model, the LA-Sepsis CPN will 
be reintegrated within the Treat model. 
SepsisFinder: Standalone risk-assessment 
The SepsisFinder model, which had greater predictive power than that seen in 
published versions of the Treat model, has value as a standalone system. The future 
of SepsisFinder is in its use as an “intelligent biomarker”. 
The future strategy for the development of SepsisFinder is fundamentally different to 
that used in the development of existing clinical scores. Typically, clinical scores 
focus on information and measurements that are easily obtained at the bedside. 
However, the integration of hospital wide electronic health records and other IT 
systems present an opportunity for easy access to a greater amount of information. 
Furthermore, it allows the departure from the subjective evaluations often required at 
the bedside, moving towards the use of objective, measured data. Throughout the 
PostDoc project, Sepsisfinder will be refined and tested clinically, and a laboratory-
variable-only version, SepsisFinderLite will be created. 
Risk-assessment software such as SepsisFinder or SepsisFinderLite also has 
immediate commercial potential. Reliable, model-based stratification of patients into 
risk-groups provides an opportunity to identify target populations to improve cost-
effectiveness. For example, a group of high-risk patients may be eligible for 
expensive rapid diagnostic testing in addition to routine blood cultures. 
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Early-Warning and Treatment revision 
The models described in this dissertation may also be extended to create a more 
complete picture of the response to sepsis by adding a temporal dimension. 
The entire time-course of the infection should be considered: until now, point 
estimates of the risk of bacteraemia/30-day mortality have been made at the time 
when a patients is clinically recognised as having an infection. This use is valuable 
in and of itself as an initial triage tool/risk-stratification and impacts decisions on 
patient workup/treatment. However, this intelligent biomarker may also be useful 
at other time points. 
One such use could be as an in-hospital monitoring tool for the early detection of 
hospital-acquired infections. The impact of such technology would be significant, 
since time is critical in sepsis patients. Early identification of infection has the 
potential to reduce the time to diagnosis and appropriate, live-saving treatment. 
An intelligent tool for assessing the clinical success or failure of antibiotic treatment 
is also needed; the causative pathogen (and hence the susceptibility to antibiotics) is 
found in less than half of all patients with an infection. For these patients, there is no 
objective measure of whether the treatment is appropriate and it is difficult to justify 
treatment escalation or de-escalation. It is hoped that a SepsisFinder module can 
provide support for the decision to revise treatment. 
Re-integration within Treat 
The original goal of tuning the Sepsis CPN was to improve the overall performance 
of Treat’s decision support. The improvements seen in the predictive performance of 
the standalone versions of the Sepsis CPN provide reason to believe that re-
integration will give an improvement in performance. Additionally, Treat includes 
information on the site of infection, which is related to mortality (Chapter 4). 
Therefore, it is expected this can further improve performance. However, the re-
integration is not a trivial cut and paste task. Re-integration will involve some degree 
of automatic learning in the full Treat CPN. To our knowledge, there is no existing 
descriptions of learning in such large CPNs, and computational problems are bound 
to arise. 
Treat Steward, the software package which includes the Treat CPN, is a fully 
integrated system that combines antimicrobial stewardship with advanced decision 
support. The purpose of antimicrobial stewardship is to promote the rational use of 
antimicrobials, preserving their effectiveness as the prevalence of resistant microbes 
increases. It is hoped that the improvements made to Treat Steward’s decision support 
through the re-integration of the LA-Sepsis CPN will help in the fight against 
antimicrobial resistance. 
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